A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease

Kidney International

Volumn 87, Issue 3, 2015, Pages 564-574

  Spinale, Joann M ^a   Mariani, Laura H ^b,c   Kapoor, Shiv ^d   Zhang, Jidong ^d   Weyant, Robert ^b   Song, Peter X ^c   Wong, Hetty N ^d   Troost, Jonathan P ^c   Gadegbeku, Crystal A ^e   Gipson, Debbie S ^c   Kretzler, Matthias ^c   Nihalani, Deepak ^d   Holzman, Lawrence B ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; RECOMBINANT PROTEIN; UROKINASE RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; URINE LEVEL; ADOLESCENT; ALBUMINURIA; ANIMAL; BLOOD; CHILD; CLINICAL TRIAL; FOCAL GLOMERULOSCLEROSIS; GENETICS; GLOMERULONEPHRITIS; IMMUNOGLOBULIN A NEPHROPATHY; LIPOID NEPHROSIS; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; TRANSGENIC MOUSE; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ALBUMINURIA; ANIMALS; BIOMARKERS; CHILD; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEPHROSIS, LIPOID; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84926612863     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.346     Document Type: Article

References (32)

1. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009; 27: 157-172
2. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17: 952-960
3. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010; 584: 1923-1930
4. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11: 23-36
5. Holst-Hansen C, Hamers MJ, Johannessen BE, et al. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer. 1999; 81: 203-211
6. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010; 268: 296-308
7. Trimarchi H. Primary focal and segmental glomerulosclerosis and soluble factor urokinase-Type plasminogen activator receptor. World J Nephrol. 2013; 2: 103-110
8. Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from renal allograft disease registry. Transplant Proc. 1999; 31: 223-224
9. Xu Y, Berrou J, Chen X, et al. Induction of urokinase receptor expression in nephrotoxic nephritis. Exp Nephrol. 2001; 9: 397-404
10. Wei C, Moller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008; 14: 55-63
11. Meijers B, Maas RJ, Sprangers B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014; 85: 636-640
12. Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012; 23: 2051-2059
13. Bock ME, Price HE, Gallon L, et al. Serum soluble urokinase-Type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol. 2013; 8: 1304-1311
14. Sinha A, Bajpai J, Saini S, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014; 85: 649-658
15. Wada T, Nangaku M, Maruyama S, et al A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 2014; 85: 641-648
16. Franco Palacios CR, Lieske JC, Wadei HM, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013; 96: 394-399
17. Cathelin D, Placier S, Ploug M, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol. 2014; 25: 1662-1668
18. Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013; 83: 749-756
19. Harita Y, Ishizuka K, Tanego A, et al. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol. 2014; 29: 1553-1560
20. Huang J, Liu G, Zhang YM, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 2013; 84: 366-372
21. Segarra A, Jatem E, Quiles MT, et al. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis]. Nefrologia. 2014; 34: 53-61
22. Kristensen P, Eriksen J, Blasi F, et al. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol. 1991; 115: 1763-1771
23. Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24: 1655-1663
24. Gårdsvoll H, Gilquin B, Le Du MH, et al. Characterization of the functional epitope on the urokinase receptor: complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem. 2006; 281: 19260-19272
25. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489: 57-74
26. Degryse B, Resnati M, Czekay RP, et al. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem. 2005; 280: 24792-24803
27. Luther T, Kotzsch M, Meye A, et al. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb Haemost. 2003; 89: 705-717
28. Moeller MJ, Soofi A, Sanden S, et al. An efficient system for tissue-specific overexpression of transgenes in podocytes in vivo. Am J Physiol Renal Physiol. 2005; 289: F481-F488
29. Muzumdar MD, Tasic B, Miyamichi K, et al A global double-fluorescent Cre reporter mouse. Genesis. 2007; 45: 593-605
30. Levey AS, Stevens LA, Schmid CH, et al A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612
31. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20: 629-637
32. Clinical Chemistry. Interpretation and Techniques, 3rd edn Lea & Febiger: Philadelphia, PA, USA, 1988